Sentences with phrase «for animal therapy»
Although the scientific evidence for animal therapy is still controversial, anecdotes suggest that for some kids, four - legged friends might make all the difference.
https://www.scientificamerican.com/ Not exact matches
For the health and safety of your animal and ours, emotional support / comfort / therapy animals and pets are not permitted within Shedd Aquarium.
The researchers caution that the booster therapy used in their new study will not be available on the market or even for use in human trials anytime soon; it must await years of animal testing for safety and effectiveness first.
Researchers at the Center for Engineering MechanoBiology (CEMB), an NSF Science and Technology Center at the University of Pennsylvania, study plants like this Arabidopsis thaliana to learn how molecules, cells and tissues integrate mechanics within plant and animal biology, with the aim of creating new materials, biomedical therapies and agricultural technologies.
The permanent gene therapy method could be a nonsurgical contraceptive approach for pets or stray animals.
For this technique to work, the animals first have to undergo gene therapy four weeks before the device is implanted.
The new method may make some types of gene therapy easier and could be a boon for researchers hoping to control gene activity in animals, scientists say.
Because the researchers found that CTLA4Ig was effective in suppressing hepatitis in this study, they suggest that CTLA4Ig should be among the therapeutic options investigated further as a potential therapy for patients with severe acute hepatitis B. To this end, this animal model is useful for virological and immunological analysis of HBV infection.
At the moment there are no therapies for humans and animals, but many new variants of immunotherapy have entered trial phase.
«Animals with severe cases of diarrhea lose a lot of fluid, so rehydration is the most important therapy for diarrheal illnesses.
The ability to treat large areas of the spinal cord for extended periods of time in animals «will be important for scaling up to the larger human spinal cord for future translation of this therapy to the clinic,» she added.
Researchers at the University of Minnesota have developed an animal research model for facioscapulohumeral muscular dystrophy (FSHD) to be used for muscle regeneration research as well as studies of the effectiveness of potential therapies for FSHD.
«This landmark study draws the conclusion in pre-clinical animal studies that stem cell therapy for disc degenerative disease might be a potentially effective treatment for the very common condition that affects people's quality of life and productivity,» said the senior author, Wenchun Qu, MD, PhD, of the Mayo Clinic in Rochester, Minn..
The journal's home page explains that translational medicine «builds on basic research advances — studies of biological processes using cell cultures, for example, or animal models — and uses them to develop new therapies or medical procedures.»
Our studies have improved our understanding of the basic biology underlying MMA, created a novel animal model for testing interventions and, now, led us to the promise of a new therapy.»
Stem cell therapy is acknowledged as having great potential for the treatment of a variety of diseases in both people and animals.
In their report that has received advance online publication in Nature Nanotechnology, a research team based at the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH) describes how a nanomedicine that combines photodynamic therapy — the use of light to trigger a chemical reaction — with a molecular therapy drug targeted against common treatment resistance pathways reduced a thousand-fold the dosage of the molecular therapy drug required to suppress tumor progression and metastatic outgrowth in an animal model.
«Given the limited number of successful therapies available today for repairing lost tissues, we need to look to animals like zebrafish for new clues about how to stimulate regeneration.»
One of the most promising avenues for developing a cure, however, is through gene therapy, and to create those therapies requires animal models of disease that closely replicate the human condition.
Today, mice are the undisputed top animal for research on mental health therapies.
The lack of an animal model has also prevented scientists from testing and fine - tuning experimental therapies for people.
For the animal experiments, Savio Woo of the Center for Gene Therapy at Baylor College of Medicine in Houston and his colleagues first isolated liver cells from transgenic mice that produce the human protein a1 - antitrypsin in their livers, from where it is secreted into the bloFor the animal experiments, Savio Woo of the Center for Gene Therapy at Baylor College of Medicine in Houston and his colleagues first isolated liver cells from transgenic mice that produce the human protein a1 - antitrypsin in their livers, from where it is secreted into the blofor Gene Therapy at Baylor College of Medicine in Houston and his colleagues first isolated liver cells from transgenic mice that produce the human protein a1 - antitrypsin in their livers, from where it is secreted into the blood.
ASCB President Don Cleveland of the University of California, San Diego, said his team just published an animal study on a gene silencing therapy for treating a form of Lou Gehrig's disease that they now hope to move to clinical studies.
The findings have implications for all aspects of medical and scientific research because laboratory mice underpin studies whose results have a transformative effect on human and animal lives through vaccination and other immune - based therapies.
This conference touched on a broad spectrum of topics encompassing scientific integrity, including gene therapy, guidelines for animal and human subject use, authorship, public health issues, and the involvement of minorities in research.
The results, published in the current issue of Human Molecular Genetics, open the door for pursuing gene editing in nonhuman primates as models for new therapies, including pharmacological, gene - and stem cell - based therapies, said Keith Latham, MSU animal science professor and lead author of the study.
What has been more surprising to the researchers is not that the improvements have held for the year — that much had already been documented in animal studies — but that, at least in one of the patients, the therapy helped train the eye to see better.
Researchers have pursued alternative therapies for TB using a variety of animal models, including the zebrafish found in many pet stores and household aquariums.
«The new animal model opens the door for scientists to conduct needed mechanistic studies and identify preventative therapies to minimize this painful and debilitating condition,» Banga said.
In partnership with the Italian Cystic Fibrosis Research Foundation, we founded a CF animal Core Facility (CFaCore) as a platform for pre-clinical studies and for testing novel antibacterial or anti-inflammatory therapies.
BETHESDA, Md., Mon., Jan. 26, 2004 - A Japanese - U.S. team today reported the successful creation of transgenic animals using sperm genetically modified and grown in a laboratory dish, an achievement with implications for a wide range of research from developmental biology to gene therapy.
His major research interests are human neuroanatomy and neuropathology and the use of animal models to test novel therapies for neurodegenerative diseases including Alzheimer's disease.
Thus, MGE, or MGE - like, precursors provide a great opportunity for cell - based therapy in animal models of neurological disorders linked to impaired inhibitory function.
Present use cases for the utility of animal models for identifying targets for precision therapies
«Many optogenetic experimental designs can now be applied to completely normal tissues or animals, greatly extending the scope of these research tools and possibly allowing for new therapies involving neuronal photostimulation.»
Researchers from the University of California, San Diego (UCSD) School of Medicine, the Center for Neurologic Study and Isis Pharmaceutical Corporation have designed and tested a molecular therapy in animals that they hope will be a major development in the fight to treat amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease.
The comprehensive information presented for each cell therapy includes: an overview of the therapy, a list of therapeutic cells utilized in the specific treatment, mode and regimen of cell delivery, mechanism of action, formulation, in vitro data, animal models, preclinical data and related clinical trials.
Both recent experience with immunotherapy for clearance of Aβ in AD, and their own (and Prothena's) experience with AS - clearing immunotherapies in animal models, indicate that in order to be effective as disease - modifying agents when administered alone, therapies that remove proteinaceous aggregates from the brain must be initiated in the early clinical or even preclinical stages of the disease, before the burden of other forms of aging damage becomes entrenched.
Each cell - based treatment approach is presented as a potential therapy for a specific disease or a disease category (e.g.: cardiovascular diseases, metabolic diseases, etc.), studied in animal models or in humans.
Graber will also lead the development of the Comparative Models of Regeneration Database (RegenDB), a novel bioinformatics resource supported by the National Institutes of Health (NIH) whose function is to integrate gene function across multiple animal, tissue and cell models in order to validate and inform the hypotheses needed for the discovery and development of regenerative medicine drug therapies.
Researchers could potentially be able to get a better sense of whether a CRISPR therapy in monkeys will translate to cures for people if the animals had the same disease - causing mutations as humans.
The track record of animal models for predicting therapies that will work in people has been poor, making drug discovery for neurodegenerative diseases very costly — and therefore less attractive to drug companies.
To build upon the encouraging early discoveries, Helmsley renewed and expanded its Crohn's funding for the Institute in 2013 to begin new work with three major aims: 1) continue studies of individual genes to determine how genetic differences between Crohn's patients and healthy individuals contribute to the disease; 2) evaluate promising small molecules in disease - relevant studies and prioritize insights from genetics to help develop novel therapeutics; and 3) begin basic experimentation in animal models with Crohn's disease to provide the data necessary to begin testing new therapies in humans.
Research with animals continues to be indispensable for understanding basic physiological mechanisms and develop and improve therapies for humans and animals alike.
Targets of research range from basic molecular and cellular mechanisms, the manipulation of these mechanisms in animal models, analyses of the genes and gene products in cardiovascular disease, and clinical research that seeks to improve diagnosis and therapy for patients.
Working with animal models, researchers at Joslin Diabetes Center now have demonstrated the potential of giving a drug in combination with tPA that might improve stroke outcomes and increase the window of opportunity for the therapy.
2010 — Investigator, Institute of Laboratory Animal Sciences and Max - Planck - Partner - Group on Stem Cell Aging, Chinese Academy of Medical Sciences 2007 — 2009 Associate Investigator, Institute of Laboratory Animal Sciences and Max - Planck - Partner - Group on Stem Cell Aging, Chinese Academy of Medical Sciences 2007 Posdoc Fellow at Department of Molecular Medicine and Max - Planck - Research - Group on Stem Cell Aging, Ulm University 2005 Guest scientist at Laboratory of Stem Cell Therapy, Institute of Medical Science, University of Tokyo 2003 — 2004 Visiting Scientist at Gene Mapping Center, Max Delbr ¨ ¹ ck Center, Berlin, Germany 2001 — 2003 Research Assistant, Sino - German Laboratory for Molecular Medicine, Fu Wai Hospital & Cardiovascular Institute, Peking Union Medical College, Chinese Academy of Medical Sciences 1997 — 1998 Resident Physician, Youjian Hospital, Shangdong, China
They suggest that further research should be performed over a longer time period and in a greater number of animals to determine whether these improvements are maintained, and look forward to further work utilizing membrane - spanning peptides for presentation of bioactive molecules for stem cell therapy.
He has developed laboratory and animal models of the tumor in its microenvironment, which have allowed for both identification of novel targets and validation of novel targeted therapies.
Basic research presentations at 2016 American Heart Association Scientific Sessions: cell therapy for heart attack (mesenchymal stem cells) in animal models and role of CD73, gradual release drug for atrial fibrillation, how particles from stored blood affects blood vessels.